Researchers at Adelaide University have developed targeted mRNA lipid nanoparticles that reprogram immunosuppressive cells inside solid tumors, according to a study published in Science Advances. By delivering mRNA instructions alongside the compound Resiquimod directly to tumor-associated macrophages, the cross-disciplinary team of engineering, biomedical, oncology, and immunology experts bypassed key immune barriers that normally stop cytotoxic T cells from attacking cancer.
How Targeted Lipid Nanoparticles Reprogram Tumor Macrophages
Solid tumors often evade the body’s defenses by surrounding themselves with tumor-associated macrophages (TAMs), which are white blood cells that suppress anti-cancer immune responses. According to Adelaide University researchers, these macrophages make it difficult for cytotoxic T cells to infiltrate the tumor environment. To alter this dynamic, the scientific team engineered lipid nanoparticles—utilizing the same delivery technology found in COVID-19 vaccines—coated with an antibody that recognizes the TREM2 protein expressed heavily on immunosuppressive TAMs.
Once the nanoparticles target these macrophages, they release two active ingredients: an mRNA molecule carrying instructions to produce CXCL9, and Resiquimod. According to findings published in Science Advances, Resiquimod switches the macrophages away from their immune-suppressing behavior, while CXCL9 acts as a chemical beacon to attract cancer-fighting CD8+ T cells into the tumor site.
Animal Experiment Results and Checkpoint Inhibitor Combination Tests
The treatment also increased tumor CXCL9 levels fourfold, drove greater numbers of active CD8+ T cells into the tumors, and yielded a moderate reduction in overall tumor growth.
When researchers combined the nanoparticle treatment with existing immune checkpoint-blocking drugs targeting PD-L1 and CTLA-4, they observed further increases in cancer-fighting T cells and an elevation in central memory T cells, which help the immune system remember and respond to future threats. However, according to the study data, this combination did not produce additional tumor-growth inhibition in the specific mouse model tested, as the 4T1 model is known to respond poorly to PD-L1 and CTLA-4 inhibitors.
Future Outlook for Solid Tumor Immunotherapy
Lead researcher Professor Chunxia Zhao noted that the findings offer an important proof of concept for altering the immune environment of solid cancers from within. While the system was well-tolerated in mice with minimal effects detected in healthy organs, the study authors cautioned that systemic inflammation and long-term toxicity require further investigation before clinical trials in human patients can begin.
Frequently Asked Questions
What is the primary function of tumor-associated macrophages in cancer?
Tumor-associated macrophages (TAMs) are immune cells found abundantly within tumors that typically suppress the body’s anti-cancer immune response and prevent cytotoxic T cells from infiltrating the cancer tissue.
What payload do the newly developed mRNA nanoparticles deliver?
According to the study in Science Advances, the nanoparticles deliver an mRNA molecule that instructs cells to produce the chemical signal CXCL9, alongside the compound Resiquimod to alter macrophage behavior.
Are these mRNA nanoparticles ready for human clinical use?
No. Lead researcher Professor Zhao stated that while the animal experiments show encouraging proof of concept, significant work remains before the approach can be considered for human patients.
What are your thoughts on this breakthrough in mRNA cancer immunotherapy? Share your perspective in the comments below, and subscribe to our newsletter for the latest updates in oncology research.
Keep reading